Jamison Private Wealth Management Inc. Has $3.10 Million Holdings in Pfizer Inc. (NYSE:PFE)

Jamison Private Wealth Management Inc. cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 122,357 shares of the biopharmaceutical company’s stock after selling 4,391 shares during the period. Jamison Private Wealth Management Inc.’s holdings in Pfizer were worth $3,101,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $27,000. Gould Capital LLC grew its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer in the fourth quarter valued at about $30,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Citigroup reissued a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Stock Performance

Shares of Pfizer stock opened at $23.97 on Friday. The firm has a market cap of $136.27 billion, a price-to-earnings ratio of 17.37, a price-to-earnings-growth ratio of 0.87 and a beta of 0.57. The stock’s 50-day moving average is $23.26 and its 200-day moving average is $24.90. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the company posted $0.82 earnings per share. Pfizer’s revenue was down 7.8% on a year-over-year basis. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.18%. Pfizer’s payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.